Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Equity to Asset 0.56
NVS's Equity to Asset is ranked lower than
60% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NVS: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
NVS' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.56
0.51
0.65
Interest Coverage 11.93
NVS's Interest Coverage is ranked lower than
71% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.94 vs. NVS: 11.93 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 11.93  Med: 16.6 Max: 30.91
Current: 11.93
11.93
30.91
F-Score: 5
Z-Score: 2.40
M-Score: -2.67
WACC vs ROIC
7.54%
7.50%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 17.09
NVS's Operating margin (%) is ranked higher than
75% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.61 vs. NVS: 17.09 )
Ranked among companies with meaningful Operating margin (%) only.
NVS' s Operating margin (%) Range Over the Past 10 Years
Min: 17.09  Med: 20.94 Max: 22.35
Current: 17.09
17.09
22.35
Net-margin (%) 13.69
NVS's Net-margin (%) is ranked higher than
75% of the 732 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. NVS: 13.69 )
Ranked among companies with meaningful Net-margin (%) only.
NVS' s Net-margin (%) Range Over the Past 10 Years
Min: 13.69  Med: 19.02 Max: 35.29
Current: 13.69
13.69
35.29
ROE (%) 9.12
NVS's ROE (%) is ranked higher than
60% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. NVS: 9.12 )
Ranked among companies with meaningful ROE (%) only.
NVS' s ROE (%) Range Over the Past 10 Years
Min: 9.12  Med: 15.32 Max: 25.73
Current: 9.12
9.12
25.73
ROA (%) 5.14
NVS's ROA (%) is ranked higher than
59% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NVS: 5.14 )
Ranked among companies with meaningful ROA (%) only.
NVS' s ROA (%) Range Over the Past 10 Years
Min: 5.14  Med: 8.97 Max: 16.19
Current: 5.14
5.14
16.19
ROC (Joel Greenblatt) (%) 39.36
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.31 vs. NVS: 39.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 36.01  Med: 59.62 Max: 69.75
Current: 39.36
36.01
69.75
Revenue Growth (3Y)(%) 1.80
NVS's Revenue Growth (3Y)(%) is ranked lower than
61% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. NVS: 1.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.9  Med: 2.3 Max: 12.3
Current: 1.8
-3.9
12.3
EBITDA Growth (3Y)(%) -7.20
NVS's EBITDA Growth (3Y)(%) is ranked lower than
77% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. NVS: -7.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.6  Med: 0.6 Max: 11.6
Current: -7.2
-7.6
11.6
EPS Growth (3Y)(%) -6.90
NVS's EPS Growth (3Y)(%) is ranked lower than
69% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NVS: -6.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.1  Med: 3.5 Max: 82
Current: -6.9
-7.1
82
» NVS's 10-Y Financials

Financials (Next Earnings Date: 2017-01-26)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVS Guru Trades in Q1 2016

Tom Gayner 3,700 sh (New)
John Rogers 13,296 sh (+18.01%)
Sarah Ketterer 316,362 sh (+12.30%)
Jim Simons 3,264,498 sh (+5.61%)
Manning & Napier Advisors, Inc 3,638,373 sh (+3.73%)
Murray Stahl 29,250 sh (+1.74%)
Ken Fisher 6,287,099 sh (+1.59%)
PRIMECAP Management 20,938,858 sh (+0.82%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Dodge & Cox 45,054,916 sh (-0.12%)
Tweedy Browne 237,664 sh (-1.87%)
Mario Gabelli 6,865 sh (-7.10%)
Mairs and Power 3,780 sh (-7.35%)
Samuel Isaly 457,700 sh (-48.86%)
» More
Q2 2016

NVS Guru Trades in Q2 2016

John Rogers 14,818 sh (+11.45%)
Ken Fisher 6,363,641 sh (+1.22%)
Sarah Ketterer 319,351 sh (+0.94%)
Kahn Brothers 27,643 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Mairs and Power 3,780 sh (unchged)
Murray Stahl 29,250 sh (unchged)
Tom Gayner 3,700 sh (unchged)
PRIMECAP Management 20,831,508 sh (-0.51%)
Dodge & Cox 44,366,511 sh (-1.53%)
Tweedy Browne 233,783 sh (-1.63%)
Manning & Napier Advisors, Inc 3,564,657 sh (-2.03%)
Mario Gabelli 6,015 sh (-12.38%)
Jim Simons 2,260,598 sh (-30.75%)
Samuel Isaly 255,700 sh (-44.13%)
» More
Q3 2016

NVS Guru Trades in Q3 2016

Mairs and Power 6,354 sh (+68.10%)
Jim Simons 2,515,098 sh (+11.26%)
Manning & Napier Advisors, Inc 3,752,105 sh (+5.26%)
Mario Gabelli 6,265 sh (+4.16%)
Sarah Ketterer 321,258 sh (+0.60%)
Tom Gayner 3,700 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Murray Stahl 29,250 sh (unchged)
Samuel Isaly 255,700 sh (unchged)
PRIMECAP Management 20,557,433 sh (-1.32%)
Dodge & Cox 43,581,886 sh (-1.77%)
Ken Fisher 6,065,150 sh (-4.69%)
Tweedy Browne 220,115 sh (-5.85%)
John Rogers 13,914 sh (-6.10%)
» More
Q4 2016

NVS Guru Trades in Q4 2016

Ken Fisher 6,074,870 sh (+0.16%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:MRK, NYSE:PFE, NYSE:SNY, NYSE:ABBV, NYSE:BMY, OTCPK:GLAXF, OTCPK:BAYZF, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:GWPRF, NAS:HCM » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includesmedicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.

Top Ranked Articles about Novartis AG

Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...
Does Biotech’s Recent Bounce Have Legs? Examining 3 Big Pharma stocks that dominate the making of cancer-fighting treatments
The beleaguered biotechology sector, which has endured political controversy amid charges of price gouging, is now on an upward trajectory. The Nasdaq Biotechnology Index, after falling 17.46% year to date, has jumped 9.04% over the past month. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.90
NVS's P/E(ttm) is ranked higher than
54% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. NVS: 24.90 )
Ranked among companies with meaningful P/E(ttm) only.
NVS' s P/E(ttm) Range Over the Past 10 Years
Min: 5.7  Med: 15.8 Max: 29.97
Current: 24.9
5.7
29.97
Forward P/E 14.31
NVS's Forward P/E is ranked higher than
58% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.95 vs. NVS: 14.31 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.01
NVS's PE(NRI) is ranked higher than
53% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. NVS: 25.01 )
Ranked among companies with meaningful PE(NRI) only.
NVS' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.11 Max: 31.15
Current: 25.01
10.63
31.15
Price/Owner Earnings (ttm) 17.69
NVS's Price/Owner Earnings (ttm) is ranked higher than
72% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.46 vs. NVS: 17.69 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.18  Med: 15.72 Max: 23.92
Current: 17.69
7.18
23.92
P/B 2.27
NVS's P/B is ranked higher than
59% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. NVS: 2.27 )
Ranked among companies with meaningful P/B only.
NVS' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.45 Max: 3.95
Current: 2.27
1.69
3.95
P/S 3.42
NVS's P/S is ranked lower than
57% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.91 vs. NVS: 3.42 )
Ranked among companies with meaningful P/S only.
NVS' s P/S Range Over the Past 10 Years
Min: 1.89  Med: 3.26 Max: 5.01
Current: 3.42
1.89
5.01
PFCF 19.50
NVS's PFCF is ranked higher than
53% of the 200 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.43 vs. NVS: 19.50 )
Ranked among companies with meaningful PFCF only.
NVS' s PFCF Range Over the Past 10 Years
Min: 7.05  Med: 16.76 Max: 26.68
Current: 19.5
7.05
26.68
POCF 14.12
NVS's POCF is ranked higher than
57% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.46 vs. NVS: 14.12 )
Ranked among companies with meaningful POCF only.
NVS' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.05 Max: 19.3
Current: 14.12
5.77
19.3
EV-to-EBIT 22.69
NVS's EV-to-EBIT is ranked lower than
58% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.56 vs. NVS: 22.69 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.55 Max: 27.1
Current: 22.69
8.5
27.1
EV-to-EBITDA 15.09
NVS's EV-to-EBITDA is ranked higher than
55% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.22 vs. NVS: 15.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.1 Max: 18.4
Current: 15.09
7.3
18.4
Shiller P/E 14.27
NVS's Shiller P/E is ranked higher than
91% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.99 vs. NVS: 14.27 )
Ranked among companies with meaningful Shiller P/E only.
NVS' s Shiller P/E Range Over the Past 10 Years
Min: 9.68  Med: 14.65 Max: 21.52
Current: 14.27
9.68
21.52
Current Ratio 1.05
NVS's Current Ratio is ranked lower than
86% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. NVS: 1.05 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.39 Max: 2.83
Current: 1.05
0.83
2.83
Quick Ratio 0.78
NVS's Quick Ratio is ranked lower than
83% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. NVS: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.13 Max: 2.48
Current: 0.78
0.59
2.48
Days Inventory 136.22
NVS's Days Inventory is ranked lower than
60% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. NVS: 136.22 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 155.7 Max: 183.45
Current: 136.22
117.82
183.45
Days Sales Outstanding 62.43
NVS's Days Sales Outstanding is ranked higher than
61% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.25 vs. NVS: 62.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.9 Max: 70.59
Current: 62.43
56.31
70.59
Days Payable 96.14
NVS's Days Payable is ranked higher than
67% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.85 vs. NVS: 96.14 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 96.14
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.85
NVS's Dividend Yield is ranked higher than
91% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. NVS: 3.85 )
Ranked among companies with meaningful Dividend Yield only.
NVS' s Dividend Yield Range Over the Past 10 Years
Min: 1.49  Med: 3.34 Max: 5.11
Current: 3.85
1.49
5.11
Dividend Payout 0.96
NVS's Dividend Payout is ranked higher than
67% of the 389 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. NVS: 0.96 )
Ranked among companies with meaningful Dividend Payout only.
NVS' s Dividend Payout Range Over the Past 10 Years
Min: 0.31  Med: 0.55 Max: 0.96
Current: 0.96
0.31
0.96
Dividend Growth (3y) 5.40
NVS's Dividend Growth (3y) is ranked lower than
56% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. NVS: 5.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 6.7 Max: 18.5
Current: 5.4
0
18.5
Forward Dividend Yield 3.86
NVS's Forward Dividend Yield is ranked higher than
82% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. NVS: 3.86 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.50
NVS's Yield on cost (5-Year) is ranked higher than
89% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.17 vs. NVS: 5.50 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.08  Med: 4.66 Max: 7.13
Current: 5.5
2.08
7.13
3-Year Average Share Buyback Ratio 0.60
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. NVS: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.1 Max: 2.4
Current: 0.6
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 16.10
NVS's Price/Tangible Book is ranked lower than
93% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. NVS: 16.10 )
Ranked among companies with meaningful Price/Tangible Book only.
NVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.68  Med: 4.38 Max: 12455
Current: 16.1
2.68
12455
Price/Projected FCF 1.14
NVS's Price/Projected FCF is ranked higher than
81% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. NVS: 1.14 )
Ranked among companies with meaningful Price/Projected FCF only.
NVS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.14 Max: 2.46
Current: 1.14
0.66
2.46
Price/Median PS Value 1.08
NVS's Price/Median PS Value is ranked higher than
52% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. NVS: 1.08 )
Ranked among companies with meaningful Price/Median PS Value only.
NVS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.64  Med: 1.16 Max: 3.11
Current: 1.08
0.64
3.11
Price/Graham Number 4.28
NVS's Price/Graham Number is ranked lower than
84% of the 459 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.23 vs. NVS: 4.28 )
Ranked among companies with meaningful Price/Graham Number only.
NVS' s Price/Graham Number Range Over the Past 10 Years
Min: 1.27  Med: 2.01 Max: 81.67
Current: 4.28
1.27
81.67
Earnings Yield (Greenblatt) (%) 4.37
NVS's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. NVS: 4.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 6.4 Max: 11.8
Current: 4.37
3.7
11.8
Forward Rate of Return (Yacktman) (%) 4.12
NVS's Forward Rate of Return (Yacktman) (%) is ranked lower than
58% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.63 vs. NVS: 4.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1  Med: 13.8 Max: 61.6
Current: 4.12
1
61.6

More Statistics

Revenue (TTM) (Mil) $49,634
EPS (TTM) $ 2.85
Beta0.73
Short Percentage of Float0.22%
52-Week Range $66.93 - 83.58
Shares Outstanding (Mil)2,375.50

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 49,460 50,121 53,400
EPS ($) 4.72 4.92 5.68
EPS w/o NRI ($) 4.72 4.92 5.68
EPS Growth Rate
(3Y to 5Y Estimate)
3.50%
Dividends Per Share ($) 2.79 2.88 3.13
» More Articles for NVS

Headlines

Articles On GuruFocus.com
2 Top Health Care Dividend Stocks Jan 12 2017 
7 Stocks With Low P/S Ratios Jan 11 2017 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
Novartis Is Surviving Oct 03 2016 
A Double Dose of Trouble at Novartis Sep 22 2016 
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth Aug 31 2016 

More From Other Websites
Novartis CEO: Trump Understands Value of Drug Innovation Jan 20 2017
CSL shares jump on profit upgrade Jan 19 2017
CSL shares rally on profit guidance hike Jan 18 2017
Mallinkrodt Shares Tank Despite $100 Million FTC Deal Jan 18 2017
Novartis CEO Discusses Impact of Trump on Drug Industry Jan 18 2017
Trump tax cuts could mean more Novartis investment in U.S. Jan 18 2017
Trump tax cuts could mean more Novartis investment in U.S Jan 18 2017
Trump tax cuts could mean more Novartis investment in U.S Jan 18 2017
How Did Novartis’s Innovative Medicines Segment Perform? Jan 17 2017
How Is Novartis’s Revenue Trending? Jan 16 2017
How Did Novartis Perform in 3Q16? Jan 16 2017
5 Trump-Proof Pharma Dividends Up To 5.3% Jan 16 2017
How Does Novartis’s Valuation Compare to Peers? Jan 16 2017
Novartis to Conduct Trial on Obese, Type II Diabetes Patients Jan 13 2017
[$$] Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs Jan 13 2017
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit Jan 13 2017
Drug makers, auto stocks yank European stocks lower for first time in 3 days Jan 12 2017
Ionis’ Stocks Surge After Novartis Deal (IONS) Jan 11 2017
European stocks trim gains after Trump comments send drug stocks lower Jan 11 2017
Novartis AG downgraded by Credit Suisse Jan 11 2017
Todd Hagopian's Top Biotech Takeover Targets For 2017 Jan 10 2017
Trumponomics Is Finally Reflating Europe And Japan Jan 09 2017
Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation Jan 09 2017
Novartis joins forces with Ionis on cardiovascular treatments Jan 06 2017
Novartis joins forces with Ionis on cardiovascular treatments Jan 06 2017
Out-licensing of COPD products in the US Dec 21 2016
Licensing agreement signed for the launch of Utibron/Seebri in the US Dec 21 2016
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc. Dec 20 2016
Novartis says reaches agreement to buy Texas-based Encore Vision Dec 20 2016
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new... Dec 19 2016
Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset... Dec 16 2016
Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and... Dec 16 2016
Novartis says buys Ziarco Group to expand skin care portfolio Dec 16 2016
Novartis says buys Ziarco Group to expand skin care portfolio Dec 16 2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited Dec 16 2016
3 reasons to buy GlaxoSmithKline plc’s 5.5% yield before the market catches on Dec 12 2016
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain... Nov 21 2016
Novartis acquires US pharma research firm Selexys Pharmaceuticals Nov 21 2016
Novartis commends publication of major report which recommends broad use of dual bronchodilators to... Nov 21 2016
Novartis acquires US pharma research firm Selexys Pharmaceuticals Nov 20 2016
Novartis backs off from 2016 date for testing Google autofocus lens Nov 18 2016
Novartis backs off from 2016 date for testing Google autofocus lens Nov 18 2016
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood... Nov 16 2016
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and... Nov 15 2016
The Novartis house that Vasella built gets extreme makeover Nov 14 2016
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML... Nov 14 2016
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3... Nov 14 2016
Novartis improves ranking in 2016 Access to Medicine Index Nov 13 2016
Novartis, Pfizer cut prices to win UK approval for cancer drugs Nov 09 2016
Novartis, Pfizer cut prices to win UK approval for cancer drugs Nov 09 2016
Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (Ribociclib) Plus... Nov 01 2016
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2-... Nov 01 2016
Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration;... Oct 25 2016
Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months... Oct 09 2016
Big Pharma vs Big Pharma in court battles over biosimilar drugs Oct 03 2016
Big Pharma vs Big Pharma in court battles over biosimilar drugs Oct 02 2016
Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
Novartis bid to sell new biosimilar crimped by U.S. court battles Aug 31 2016
Turkey's investigation into drugmaker Novartis 'ongoing' -official Aug 17 2016
Turkey's investigation into drugmaker Novartis 'ongoing' -official Aug 17 2016
Turkey's investigation into drugmaker Novartis 'ongoing' - official Aug 17 2016
Novartis says bribe allegations in Turkey groundless, matter closed Aug 12 2016
Novartis could face S.Korea sales ban amid corruption allegations: media Aug 11 2016
AstraZeneca a bid target again? CEO says someone may spot value Jul 28 2016
AstraZeneca a bid target again? CEO says someone may spot value Jul 28 2016
AstraZeneca a takeover target again? CEO not commenting Jul 28 2016
Novartis in no rush to sell down stake on GSK consumer venture Jul 19 2016
Novartis in no rush to sell down stake on GSK consumer venture Jul 19 2016
Novartis, world's top drugmaker, plays down Brexit threat Jul 19 2016
Novartis, world's top drugmaker, plays down Brexit threat Jul 19 2016
AstraZeneca resolves Faslodex patent litigation in U.S. Jul 13 2016
Roche skin cancer drugs "too expensive", says UK cost agency Jun 16 2016
Novartis study shows skin cancer combo also works on lungs Jun 06 2016
British biopharma start-up Mereo to list in London Jun 05 2016
British biopharma start-up Mereo to list in London Jun 05 2016
Novartis willing to sell Roche stake without demanding premium - CEO May 25 2016
Novartis willing to sell Roche stake without demanding premium - CEO May 25 2016
Indian shares snap 4 days of losses on better corporate earnings May 24 2016
Novartis splits drugs business into two, pharma chief to leave May 17 2016
Novartis splits drugs business into two, pharma chief to leave May 17 2016
Drugs giant GSK reports slump in profits Apr 27 2016
Novartis to prepare the sale of its Roche stake, paper says Apr 25 2016
Exclusive - Novartis investigating $85 million bribery allegations in Turkey Mar 29 2016
Sun hopes cut-price generic Gleevec will win third of U.S. market Feb 01 2016
Sun hopes cut-price generic Gleevec will win third of U.S. market Feb 01 2016
Big Pharma's bet on Big Data creates opportunities and risks Jan 26 2016
U.S. FDA warns Novartis on manufacturing violations at 2 India plants Oct 28 2015
Novartis profit hit by $390 mln settlement in U.S. kickbacks case Oct 27 2015
Roche shows its intent with Switzerland's tallest skyscraper Sep 18 2015
Novartis flags margin increase, higher dividends, bolt-on deals Jun 18 2015
Novartis India arm says unaware of any delisting plan Jun 11 2015
GSK scraps plan to list HIV drugs business and shields dividend May 06 2015
Interview - New-look GSK bets on consumer health spending May 06 2015
Doubts grow over GlaxoSmithKline's $6 bln capital return plan May 01 2015
Novartis posts Q1 profit beat despite dollar drag Apr 23 2015
Novartis sues Cipla over respiratory drug Onbrez Dec 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)